Evidence of meeting #37 for Health in the 45th Parliament, 1st session. (The original version is on Parliament’s site, as are the minutes.) The winning word was industry.

A video is available from Parliament.

On the agenda

Members speaking

Before the committee

Godard  Director General, Natural and Non-Prescription Health Products Directorate, Department of Health
O'Connor  Director General, Health Product Compliance Directorate, Department of Health

5:35 p.m.

Director General, Health Product Compliance Directorate, Department of Health

Sara O'Connor

No, not for natural health products.

All of our recalls that we conduct are voluntary. We work with the companies to ensure that those recalls.... They have processes in place to conduct recalls. It works. We work together.

The Vice-Chair Bloc Marie-Hélène Gaudreau

I just want to let you know, Ms. Dancho, that you have only a few seconds left, enough time for a quick question.

5:35 p.m.

Conservative

Raquel Dancho Conservative Kildonan—St. Paul, MB

Thank you. I think I have 20 seconds left.

In conclusion, I would just say that our concern is that it seems to us and to many in the natural health product world that the Liberal government wants a ministerial power to be able to recall among other powers associated with therapeutic products, specifically pharmaceuticals. I'm not understanding, and we're not understanding. If the recall is important, we don't have to designate. What I'm hearing from you on these products, as pharmaceuticals, is that they could still be exclusively classified as natural health products.

That's my take. I'm not putting words in your mouth, but it sounds like I am correct in my assessment.

Thank you.

5:35 p.m.

Director General, Natural and Non-Prescription Health Products Directorate, Department of Health

Kim Godard

If I could add—

The Vice-Chair Bloc Marie-Hélène Gaudreau

I'm giving you 10 seconds. I gave her more time, so I'm giving you more time.

October 7th, 2026 / 5:35 p.m.

Director General, Natural and Non-Prescription Health Products Directorate, Department of Health

Kim Godard

—in terms of operationalizing recalls, it is not the minister who looks at the evidence. We have inspectors on the ground who are highly educated experts in the area who look at the data and then recommend a recall. The power is delegated to apolitical public servants.

5:35 p.m.

Conservative

Raquel Dancho Conservative Kildonan—St. Paul, MB

That's right, but then it goes to—

The Vice-Chair Bloc Marie-Hélène Gaudreau

Thank you very much.

We now go to Ms. Chi for four minutes.

Maggie Chi Liberal Don Valley North, ON

Thank you, Madam Chair. You look great in the chair. Congratulations.

Thank you to our Health Canada officials for appearing today and helping us work through a fairly technical regulatory framework.

At our last meeting, we heard from industry partners who were telling us that the Health Canada approval really is the gold stamp that gives industry the competitive edge globally. We know that Canadians want choice. A lot of us consume natural health products, and we want to rely on a really good, solid regulatory framework so that we know that the products we buy off the shelf are safe to consume.

I know that the classification or the regulatory framework came up a couple of times. I really want to make a clarification on how natural health products are being classified. How is it different from pharmaceuticals?

You mentioned that they are low risk and that we have a risk-based approach. If you could expand a bit on that, it would be really appreciated.

5:40 p.m.

Director General, Natural and Non-Prescription Health Products Directorate, Department of Health

Kim Godard

Thank you for the question.

Natural health products are regulated differently from drugs. If you look at the premarket approval, for example, natural health products will go through a process depending on the risk that they pose.

For example, Health Canada has developed monographs, and those monographs are pre-cleared information: For vitamin C, here are all the claims you can make about it. We have hundreds and hundreds of these monographs. If your product is linked to one of these monographs, then that is considered a low-risk claim, and it goes through the process faster. We call that class one.

We have a class two where if you have two monographs that you're combining for your products, that is slightly more complex, and the robustness increases a bit.

Finally, we have a class three for when there's a novel ingredient and Health Canada has never reviewed it. Again, the robustness of the review increases a bit.

Maggie Chi Liberal Don Valley North, ON

Thank you for that clarification.

The 2023 change was mentioned quite a bit throughout our hearings at the committee, but we know it was in response to a 2021 audit report. Maybe you can help us understand the impetus for the change and some of the risk of taking that away.

5:40 p.m.

Director General, Natural and Non-Prescription Health Products Directorate, Department of Health

Kim Godard

Indeed, the change stemmed from an audit, and the audit found some things. I'll highlight a few.

One of them was that the postmarket aspect in natural health products wasn't robust enough. One of the reasons that there were amendments in 2023 was to provide those tools so that in the postmarket space, when the products are on the market, we could take action when needed.

The other area that the audit saw as being inadequate was labelling. Again, we've introduced a label change, and we're trying to work with industry to get to a space where we hit the happy medium.

Maggie Chi Liberal Don Valley North, ON

Thanks so much.

At our last meeting, we heard again from the industry that there's really positive feedback on the regulatory reform effort that's being undertaken by Health Canada. From your exchange with my colleague Dr. Jaczek, it sounds like you're streamlining the premarket assessment and you're strengthening the postmarket monitoring.

Would that expedite approval and make natural health products that are compliant accessible more quickly to consumers in Canada?

5:40 p.m.

Director General, Natural and Non-Prescription Health Products Directorate, Department of Health

Kim Godard

That's exactly the intent. The intent is to enable industry to bring products to market faster, but the intent is also to have the tools available if something happens while the products are on the market. It's very important that we balance those two things.

Maggie Chi Liberal Don Valley North, ON

Thank you so much.

Chair, do I have time left?

The Chair Liberal Sukh Dhaliwal

You have about 40 seconds left.

Maggie Chi Liberal Don Valley North, ON

That completes my questioning.

Thank you so much for coming.

The Chair Liberal Sukh Dhaliwal

Thank you.

We'll go to Madame Gaudreau for two minutes.

Please go ahead.

Marie-Hélène Gaudreau Bloc Laurentides—Labelle, QC

I'll be brief, Mr. Chair.

I quite enjoyed being in the chair.

Here's my question.

Changes and flexibilities are expected given what happened in 2023. There is also a desire to retain control. Let's be honest, you may or may not be able to answer this. Why has a bill been brought forward in this form, when the goal at the end of the day is to reduce red tape? You're telling me that that is a commitment and that something is coming on Health Canada's end in the spring of 2027. Why, then, has this bill been introduced?

5:45 p.m.

Director General, Natural and Non-Prescription Health Products Directorate, Department of Health

Kim Godard

Do you mean Bill C‑224?

Marie-Hélène Gaudreau Bloc Laurentides—Labelle, QC

Yes. What—

5:45 p.m.

Director General, Natural and Non-Prescription Health Products Directorate, Department of Health

Kim Godard

That's not for me to say.

Marie-Hélène Gaudreau Bloc Laurentides—Labelle, QC

Well, at least I tried.

What I'm actually wondering is this: If there is no clear commitment, what should we do? I don't know whether you have a plan under way, but we'd really like to have it. Right after this, we'll be making decisions and voting. Obviously, I hear you saying that flexible measures are in the works. I figure that, with this bill, some pressure could be brought to bear, precisely to review what's working and what's not.

I have a few seconds left. Do you have any final comments before you leave?

5:45 p.m.

Director General, Natural and Non-Prescription Health Products Directorate, Department of Health

Kim Godard

Thank you for your question.

We are indeed very much working towards that. We consulted our partners in industry and the association community. We'd be happy to share the materials we sent them, if you would like.

Marie-Hélène Gaudreau Bloc Laurentides—Labelle, QC

Thank you.

Thank you, Mr. Chair.